ArticleCase reports in nephrology2026
Is it Always Safe to Administer RAS Inhibitors to Patients Who Underwent Unilateral Radical Nephrectomy?
Article in Case reports in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is it Always Safe to Administer RAS Inhibitors to Patients Who Underwent Unilateral Radical Nephrectomy?Case reports in nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compensatory increases in single-kidney glomerular filtration rate (GFR) are usually observed after unilateral radical nephrectomy. However, the influence of hemodynamically active therapies on early functional compensation remains uncertain. We describe a 65-year-old man with latent autoimmune diabetes of adulthood, nonproteinuric chronic kidney disease consistent with atherosclerotic nephropathy, and mildly reduced baseline renal function who underwent right radical nephrectomy with caval thrombus removal for clear cell renal cell carcinoma. Based on preoperative split renal function, a postnephrectomy GFR above 45 mL/min was anticipated. Despite continued treatment with ramipril and dapagliflozin, GFR at 3 months remained close to the immediate postoperative value. After discontinuation of both agents, GFR increased above the expected threshold and remained stable, without albuminuria. This observation is hypothesis-generating and suggests that combined ACE and SGLT2 inhibition may transiently attenuate early functional compensation through hemodynamic mechanisms, particularly in patients with atherosclerotic nephropathy, supporting individualized perioperative management and close renal function monitoring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.